Biotech Values

[DewDiligence]

EMIS +50%/NVO +5% on phase-2 results for oral GLP-1:

http://finance.yahoo.com/news/novo-nordisk-announces-positive-results-123700254.html

Novo Nordisk today announced that it has successfully completed the phase 2 trial for OG217SC; an oral formulation of the long-acting GLP-1 analogue semaglutide, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks.

EMIS stands to earn an undisclosed (presumably single-digit) royalty on sales if this product is commercialized.